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Background: Microglial activation plays an important role in neurodegenerative diseases by producing several
pro-inflammatory enzymes and pro-inflammatory cytokines. Lipopolysaccharide (LPS)-induced inflammation leads
to the activation of microglial cells in the central nervous system (CNS) and is associated with the pathological
mechanisms of neurodegenerative diseases, including PD, AD, and ALS. Ginseng is a natural antioxidant used
in herbal medicine and contains ginsenosides (Rb1, Rg1, Rg3, Re, and Rd), which have anti-neoplastic and
anti-stress properties.
This study demonstrates the involvement of the anti-inflammatory signaling pathway, ginsenoside-Re (G-Re),
which is one of the ginsenosides mediated by LPS-induced neuroinflammation in BV2 microglial cells.
Methods: BV2 microglial cells were pretreated with 2 μg/ml G-Re and stimulated with 1 μg/ml LPS to induce
neuroinflammation. To investigate the effect of G-Re on LPS-induced cell signaling, we performed western blotting
and immunofluorescence using specific antibodies, such as phospho-p38, COX2, and iNOS.
Results: Pretreatment with 2 μg/ml G-Re was neuroprotective against 1 μg/ml LPS-treated microglial cells.
The neuroprotective events induced by G-Re treatment in neuroinflammation occurred via the phospho-p38,
iNOS, and COX2 signaling pathways in BV2 cells.
Conclusion: Taken together, we suggest that G-Re exerts a beneficial effect on neuroinflammatory events in
neurodegenerative diseases.
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Microglial cells, which are the major immune cells in
the brain, play a pivotal role in the innate immune
response in the central nervous system (CNS) [1]. The
activation of microglia releases various neurotrophic
factors that support neuronal cell survival, in addition to
neurotoxic factors and pro-inflammatory cytokines [2].
Acute activation causes several autoimmune responses
to neuronal death and brain injury. The activation of
microglia in the CNS is associated with the pathogenesis
of a variety of neurodegenerative diseases, such as Mul-
tiple Sclerosis (MS), Alzheimer’s disease (AD), Hunting-
ton’s disease (HD), and Parkinson’s disease (PD) [3]. The
overactivation of microglia and the consequent release
of pro-inflammatory and cytotoxic factors, including the* Correspondence: yej4823@hanmail.net
†Equal contributors
Department of Medical Research, Korea Institute of Oriental Medicine, 483
Expo-ro, Yuseong-gu, Daejeon 305-811, Republic of Korea
© 2012 Lee et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortumor necrosis factor-(TNF-α), inducible nitric oxide
synthase (iNOS), and cyclooxygenase 2 (COX2), contrib-
ute to neurodegenerative processes [4].
A recent study has reported that the activation of
microglia can trigger neurotoxicity via the production of
pro-inflammatory and cytotoxic factors in neuronal cell
lines treated with lipopolysaccharide (LPS), β-amyloid,
glutamate, and arachidonate [5]. LPS, which is a bacter-
ial endotoxin, induces inflammation, tissue damage,
infection, and inflammatory responses. LPS is widely used
to activate macrophage-like cells and to simulate infection.
LPS-treated BV2 cells express CD14, interleukin-6 (IL-6),
TNF-α, resulting in increased levels of iNOS [6-8]. LPS sti-
mulates nuclear factor-κB (NF-κB), cyclic AMP-responsive
element-binding protein (CREB) and the mitogen-activated
protein kinase (MAPKs) family, including extracellular
signal-regulated kinases (ERKs), c-Jun N-terminal kinase
(JNK), and p38 MAPK [9], which have been implicated in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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iNOS, COX2, and pro-inflammatory cytokines [4,10].
Thus, the control of microglial activation has been sug-
gested as a promising therapeutic target to combat neuro-
degenerative diseases.
Ginseng, one of the most ancient herbs used in trad-
itional Chinese medicine, exhibits anti-inflammatory
properties. Active constituents with curable features can
be found in most ginseng species, including ginseno-
sides, polysaccharides, peptides, polyacetylenic alcohols,
and fatty acids. There are two major categories of ginse-
nosides; protopanaxadiols (PPD, e.g., Ra, Rb, Rc, Rd,
Rg3, Rh2) and protopanaxatriols (PPT, e.g., Re, Rf, Rg1,
Rg2, Rh1). Ginsenoside Rg1 (Rg1), one of the saponin
components of ginseng, has been widely reported for
its neuroprotective effects on the CNS. Ginsenoside-Re
(G-Re) exhibits anti-oxidative capabilities in addition to
its neuroprotective activities, and it also demonstrates
anti-hyperlipidemic and immunomodulatory therapeutic
properties [11,12], and anti-inflammatory effects [13].
Recent studies have reported that the major active ingre-
dients, including ginsenosides, exert anti-oxidant and
anti-inflammatory effects [13-15]. Wu et al. showed that
G-Re has anti-inflammatory effect by inhibition of nitric
oxide (NO) formation and NF-κB signaling in the LPS-
induced microglial cell [13].
Several studies have reported the neuroprotective
effects of Rg1 or its metabolites, but not of Re. Thus,
we investigated the anti-inflammatory effects of G-Re
on LPS-stimulated microglial BV2 cells, and we provide
insight on its molecular mechanism. We provide further
evidence for the anti-inflammatory potential of G-Re
in vitro and the involvement of the signaling molecules,
phospho-p38, iNOS, and COX2. These results provide
a scientific basis for further investigation of G-Re as




The immortalized BV2 murine microglial cell line was
provided by Dr. Sang-Myun Park (Aju University, Re-
public of Korea) and grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS
(fetal bovine serum), 100 U/ml penicillin, and 100 μg/ml
streptomycin at 37°C in an atmosphere of 5% CO2 in
air. In all of the experiments, BV2 cells were incubated
in the presence or absence of 2 μg/ml of G-Re before
the addition of LPS (Enzo, Farmingdale, NY, USA) to the
culture media.
Cell viability assay
Cell viability was assessed by an MTT (3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide) reductionassay, as described previously [16]. This assay is based
on the ability of active mitochondrial dehydrogenase to
convert dissolved MTT into water-insoluble purple for-
mazan crystals. BV2 cells were plated on 96-well plates
(2 × 104 cells/well). After 24 h of cell seeding, the BV2
cells were treated with the indicated concentrations of
G-Re for 24 h prior to 1 μg/ml of LPS treatment for an
additional 24 h. Briefly, MTT was added to each well
at a final concentration of 0.5 mg/ml, and the plates
were incubated for 1 h at 37°C. After removal of the cul-
ture medium, DMSO was added, and the plates were
shaken for 10 min to solubilize the formazan reaction
product. The absorbance at 570 nm was measured using
a microplate reader (Bio-rad, xMark). The absorbance
at 570 nm was expressed as the percent of the relative
untreated control BV2 cells and reported as the mean.
Western blot
After treatment with or without 1 μg/ml LPS in the
presence of 2 μg/ml G-Re, the cells were washed with
ice-cold PBS and lysed with RIPA lysis buffer containing
50 mM Tris–HCl pH 7.4, 1% NP-40, 0.1% SDS, 150 mM
NaCl, and the Complete Mini Protease Inhibitor Cocktail
(Roche, Basel, Switzerland). The protein concentration
was measured with a BCA Protein Assay Kit (Pierce, IL,
USA). Extracted samples (20 μg total proteins per lane)
were separated by 10% SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) and then transferred onto nitrocel-
lulose membranes (Whatman, Dassel, Germany). The
membranes were incubated with 5% skim milk to block
nonspecific protein binding and incubated with primary
antibodies for p-p38 (1:1000, Cell Signaling), p-JNK
(1:1000, Cell Signaling), α-tubulin (1:5000, Abcam), iNOS
(1:1000, BD Pharmingen), and COX-2 (1:1000, BD Phar-
mingen) in 5% skim milk overnight. After washing 3
times with TBS-T (1 M Tris–HCl pH 7.5, 1.5 M NaCl,
0.5% tween-20), the membranes were hybridized with
horseradish peroxidase-conjugated secondary antibodies
for 1 h. Then, the membranes were washed with TBS-T,
and the specific immunoreactive protein bands were
detected using the SuperSignal West Femto Chemilu-
minescent Substrate (Pierce, IL, USA) or enhanced
with chemiluminescence reagents (Amersham Pharma-
cia, NJ, USA). α-tubulin was used as an internal control
to normalize for protein loading. Protein bands were
detected and analyzed using a FusionSL4-imaging
system, and quantification of the immunoblotting bands
was performed with the Bioprofil (Bio-1D version 15.01,
viber Lourmart).
Immunofluorescence
For immunofluorescence staining, the cells were washed
with PBS, and then fixed with 4% paraformaldehyde for
15 min and permeabilized with 0.5% Triton X-100 in
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BSA in PBS-T (0.1% Triton X-100 in PBS) to reduce
nonspecific immune reactivity, and the cells were incu-
bated with primary antibodies overnight at 4°C. After
washing 3 times with PBS-T, the cells were incubated
with secondary antibodies conjugated to FITC or rhoda-
mine. Stained cells were mounted with fluorescence
mounting medium with DAPI (Vector laboratories, CA,
USA). The fluorescently stained cells were then exam-
ined using a microscope (Olympus, BX51). The number
of fluorescently stained cells was counted in each of
the three randomly chosen fields using the NIH Image J
program (version 1.46j).Data analysis
Data are expressed as the mean ± S.E.M. Comparisons
were evaluated by one-way analysis of variance
(ANOVA) with Prism software. Values that were signifi-
cantly different from the relative controls are indicated





























Figure 1 Effects of ginsenoside-Re on viability in LPS-induced BV2 mi
microglial cells. BV2 microglial cells were treated with indicated doses (0, 0
measured by an MTT assay. The values shown are the mean ± S.E.M. of dat
** p < 0.01. (B) Effects of G-Re on LPS-induced microglial cell death. BV2 ce
with 1 μg/ml LPS for 24 h in the presence or absence of G-Re. The rates of
shown are the mean ± S.E.M. of data obtained from three independent ex
and then stimulated to 1 μg/ml LPS for 24 h in the presence or absence o
microscopy with antibodies against active caspase-3. The values shown are
experiments. (bars: 50 μm.) * p < 0.05.Results
Ginsenoside-Re prevents LPS-induced microglial cell
death in BV2 microglial cells
To examine the viability of BV2 microglia after LPS
treatment, we incubated BV2 microglial cells with LPS
(1 μg/ml) at the indicated doses for 24 h. Our results
showed that LPS decreased cell survival in a dose-
dependent manner (Figure 1A). Compared to vehicles, 1
μg/ml LPS treatment of BV2 cells resulted in a decrease
in cell viability by 54%. To investigate whether G-Re
attenuated LPS-induced microglial cell death, BV2
microglial cells were treated with G-Re plus LPS. After
pretreatment of G-Re (0.5, 1 and 2 μg/ml) for 24 h, BV2
cells were treated with LPS for 24 h in the presence or
absence of G-Re. Treatment of LPS alone markedly
decreased cell survival; however, pretreatment with G-Re
reduced this decrease of cell survival by 84% at a
dose of 2 μg/ml G-Re (Figure 1B). In addition, immu-
nocytochemical analysis showed that the levels of active
caspase-3, a key enzyme that regulates cell apoptosis,
were increased at 24 h after LPS treatment. Pretreatment*
LPS LPS+G-Re
croglial cells. (A) G-Re inhibits LPS-induced cell death in BV2
.05, 0.1, 0.5 and 1 μg/ml) of LPS for 24 h, and cell viability was
a obtained from three independent experiments. n=15, * p < 0.05,
lls were pretreated for 24 h with 2 μg/ml G-Re, and then stimulated
cell survival were measured by a MTT assay at 570 nm. The values
periments. (C) BV2 cells were pretreated with 2 μg/ml G-Re for 24 h
f 2 μg/ml G-Re. Cells were visualized using immunofluorescence
the mean ± S.E.M. of data obtained from three independent
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vated caspase-3 (Figure 1C). These results indicate that
G-Re exhibits a protective role against LPS-induced
microglial cell death.
Ginsenosides-Re attenuates LPS-induced activation of
p38MAPK in BV2 microglial cells
Because the MAPK family is known to be a key player in
LPS-induced cell signaling, we examined whether G-Re
decreases the phosphorylation of the MAPK family pro-
teins, JNK and p38MAPK. To do this, BV2 microglial
cells were treated with 1 μg/ml LPS in the presence
or absence of 2 μg/ml G-Re. A significant increase in
JNK and p38 phosphorylation was observed as early as
15 min after LPS treatment (Figure 2). However, pre-
treatment with G-Re attenuated LPS-induced phosphor-
ylation of p38 in the presence of G-Re and not JNK.
Moreover, the total protein levels of JNK and p38 were
unchanged (Figure 2). These results suggest that the G-
Re-mediated attenuation of cell death is associated with
downregulation of the p38MAPK signaling pathway.
Ginsenosides-Re attenuates the protein expression of
LPS-induced pro-inflammatory mediators in BV2
microglial cells
To investigate the effect of G-Re on LPS-induced micro-
glial activation, BV2 microglial cells were treated with
1 μg/ml LPS for 18 h. LPS highly increased the protein
levels of iNOS and COX2 (Figure 3 and 4) in BV2







Figure 2 Ginsenoside-Re inhibits LPS-induced phosphorylation of p38
p38MAPK was highly increased by LPS alone and was diminished by G-Re.
stimulated with 1 μg/ml LPS for 15 min in the presence or absence of 2 μg
including the phosphorylated form of p38 and JNK. Total p38, JNK and α-tu
shown are the mean ± S.E.M. of data obtained from three independent ex
No differences were found with the G-Re alone treatments. * p < 0.05, ** ptreatment with 2 μg/ml G-Re markedly inhibited iNOS
and COX2 protein levels compared with LPS alone
(Figure 3B and 4B). As shown in Figure 3A and 4A, we
confirmed the inhibitory effect of G-Re on LPS-induced
BV2 microglial cells by immunofluorescence staining.
Stimulation of BV2 microglial cells with 1 μg/ml LPS
resulted in a notable increase in the protein expression
levels of iNOS and COX2. Compared with LPS treat-
ment alone, these expression levels were decreased by
G-Re treatment. These findings indicated that G-Re
inhibits LPS-induced pro-inflammatory protein expres-
sion in BV2 microglial cells.Discussion
The present study demonstrates that G-Re inhibits LPS-
induced pro-inflammatory mediators in BV2 microglial
cells through the blockade of the p38MAPK signaling
pathway. Stimulation of microglial cells with LPS induced
the activation of p38, which subsequently led to the upre-
gulation of iNOS and COX2 expression. G-Re also signifi-
cantly suppressed the LPS-induced expression of iNOS
and COX2 in BV2 microglial cells. Thus, our data sup-
port that p38MAPK is important for microglial cell
death and pro-inflammatory cytokine upregulation in
response to LPS and may be a therapeutic target for
neuroinflammatory diseases, where overproduction of
pro-inflammatory cytokines has been implicated in disease
progression. G-Re is one promising therapeutic approach






































MAPK in BV2 microglial cells. (A) The level of phosphorylated
BV2 cells were pretreated with 2 μg/ml G-Re for 1 h and then
/ml G-Re. Western blots were performed with specific antibodies,
bulin were used as loading controls for the cell lysates. The values







































Con G-Re LPS LPS +G-Re
Figure 3 Ginsenoside-Re attenuates the expression levels of iNOS proteins in LPS-induced BV2 microglial cells. (A) BV2 cells were
pretreated with 2 μg/ml of G-Re for 1 h, and then stimulated with 1 μg/ml LPS for 18 h in the presence or absence of 2 μg/ml G-Re. Cells were
visualized using immunofluorescence microscopy with antibody against iNOS. Quantification of iNOS expression density by Image J is shown on
the right. (n = 5 for each of the four groups.) (bars: 50 μm.) * p < 0.05, ** p < 0.01. (B) Western blots were performed using an antibody against
iNOS. The loading control for the cell lysates was determined by re-probing the membranes with α-tubulin antibody. The values shown are the
mean ± S.E.M. of data obtained from three independent experiments. * p < 0.05, ** p < 0.01.
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used in traditional Chinese medicine. Ginseng contains a
mixture of 30 heterogeneous glycosidal saponins, which
are also known as ginsenosides. Ginsenosides including
Rb1, Rg1, Rg3, Re, and Rd and their biomodulating and
immunomodulating functions in the immune system
and CNS have been examined in clinical and animal
studies [17,18]. Commonly studied ginsenosides such as
Rb1, Rg1, Rg3, Re, and Rd exhibit vasorelaxation, anti-
oxidation, and anti-cancer functions. In particular, G-Re,
a compound derived from Panax ginseng, improved
anti-diabetic effects by suppression of phospho-JNK and
NF-κB in diabetic animals [19]. In addition, G-Re
treatment improved cognitive impairment and helpless
behaviors by regulation of the noradrenergic system
in animal models [20]. However, the molecular mechan-
isms of G-Re remain unknown.Microglial cells are generally considered to be the
immune cells of the CNS. Microglial cells respond to
neuronal injury or damage with microglial activation.
Activated microglia produce large amounts of harmful
neurotoxic factors through the excess production of
cytotoxic factors, such as superoxide radicals, nitric
oxide [21], TNF-α and interleukin-1β [22]. p38MAPK is
a serine/threonine MAPK that is activated by a wide
range of environmental stressors and cytokines to induce
inflammation. p38MAPK is an important regulator of
pro-inflammatory cytokines such as iNOS and COX2
[23]. In several studies, phosphorylation/activation of
p38MAPK was increased by LPS treatment and, sub-
sequently, the p38 inhibitor suppressed LPS-induced
pro-inflammatory cytokine upregulation in BV2 micro-
glial cells [23]. This study showed that G-Re reduced







































Figure 4 Ginsenosides-Re attenuates the expression levels of COX2 proteins in LPS-induced BV2 microglial cells. (A) BV2 cells were
pretreated with 2 μg/ml of G-Re for 1 h, and then stimulated with 1 μg/ml LPS for 18 h in the presence or absence of 2 μg/ml G-Re. Cells were
visualized using immunofluorescence microscopy with antibody for COX2. Quantification of COX2 expression density by Image J is shown on
the right (n = 5 for each of the four groups.) (bars: 50 μm.) * p < 0.05, ** p < 0.01. (B) Western blots were performed using an antibody against
COX2. The loading control for the cell lysates was determined by re-probing the membranes with α-tubulin antibody. The values shown are
the mean ± S.E.M. of data obtained from three independent experiments. * p < 0.05, ** p < 0.01.
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(Figure 2). This result suggests that G-Re has a neuro-
protective role against neuroinflammation in the CNS.
However, our data indicate that LPS-induced JNK acti-
vation was not decreased by G-Re (Figure 2). Several
researchers found that ginsenoside Re, ginsenoside Rb1
and ginsenoside Rg1 has a beneficial effect in LPS-
activated microglial cell through inhibition of nitric
oxide (NO) formation and NF-κB signaling [13,24,25].
Moreover, G-Re has a neuroprotective effect against
LPS-induced cell death (Figure 1).
We treated with 0.5–100 μg/ml of G-Re to determine
cell toxicity and found that G-Re treatment did not
induce cell toxicity in BV2 cells, in accordance with a
previous paper. In addition, we found that treatment
with 2 μg/ml of G-Re inhibited LPS-induced cell death,
as well as the activation of p38MAPK and activatedcaspase-3 by LPS treatment in BV2 cells, as shown in
Figure 1C and 2A. However, we expect that a high dose
(more than 2 μg/ml) of G-Re could attenuate LPS-
induced cell death and change the expression of other
proteins to a greater extent than in the present study.
According to Wu et al.’s paper [13], they used 0.1–100
μM of G-Re. However, the effect of high-dose G-Re
seems to have been similar to that of the low dose in ni-
tric oxide or TNF-α production. In addition, the only
high dose of G-Re treatment inhibited the pJNK and
pIκBα expression. Therefore, we suggest that the effect
of G-Re treatment will be increased at a high dose,
depending on the target proteins and cell lines.
Previous studies have reported the development of
hydrogen peroxide [26,27], glutamate [28], MPP+ [29]
and β-amyloid-induced cell death [30]; however, the
mechanism by which LPS leads to microglial toxicity
Lee et al. BMC Complementary and Alternative Medicine 2012, 12:196 Page 7 of 8
http://www.biomedcentral.com/1472-6882/12/196remains obscure. In addition, it is noteworthy that G-Re
has a protective effect with a markedly attenuated
microglial response of caspase 3 activation (Figure 1).
It has been shown that the reduction of pro-
inflammatory mediators produced by microglia may at-
tenuate the severity of neuronal damage. Many studies
have demonstrated that some pro-inflammatory cyto-
kines and their reaction products are involved in chronic
inflammatory disease [31,32]. COX2, an inducible iso-
form of COX, is upregulated in inflammation. Moreover,
inducible nitric oxide synthase (iNOS) is associated with
inflammation, and its reaction product NO is involved in
various diseases, such as AD, PD and ALS [33-35]. Con-
sistent with other researchers’ previous data regarding
the signaling pathways mediated by microglial activation,
our data indicate that G-Re exhibits anti-inflammatory
effects, as shown in Figure 3 and 4.
Conclusions
This study presented that the involvement of the anti-
inflammatory signaling pathway by G-Re which is one
of the ginsenosides mediated by LPS-induced neuroin-
flammation in BV2 microglial cells. Pretreatment with
2 μg/ml G-Re was neuroprotective against 1 μg/ml LPS-
treated microglial cells. The neuroprotective events
induced by G-Re treatment in neuroinflammation
occurred via the phospho-p38, iNOS, and COX2 signal-
ing pathways in BV2 cells. Taken together, the above
in vitro findings suggest that G-Re mitigates neuro-
inflammatory events. Furthermore, there is a need to
evaluate the effect of G-Re on toxin-induced or gen-
etically engineered neuroinflammatory disease animal
models. We therefore believe that inhibition of pro-
inflammatory mediators may provide a new therapeutic
approach for treatment of neuroinflammatory disease.
In conclusion, our data provide evidence that G-Re
attenuates LPS-induced microglial toxicity and pro-
inflammatory activation, and these findings suggest that
G-Re may serve as a potential therapeutic drug to delay
neuroinflammatory progression.
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